ABSTRACT
Breast cancer is the most common cancer among women and the second leading cause of cancer death in the world. As treatments advance and survival increases among breast cancer survivors, we will continue to see more obstetric patients exposed to anthracycline drugs. Anthracycline toxicity risk is dose dependent, and any exposure to anthracyclines places obstetric patients at risk to cardiotoxicity. In this case report, we explore the potential chemotherapy toxicities of anthracycline exposure.